TheStreet’s Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on shares of BioMarin Pharmaceutical (BMRN). ‘The big bear market that’s still left is in smaller biotech stocks,’ Cramer said. ‘We solved the commodity bear market, the restaurant bear market, the retail bear market. Watch BioMarin, because if it does go higher, maybe people will start recommending all of those companies that are in biotech that have just been crushed.’ The analysts at Robert W. Baird upgraded the stock to outperform from neutral and raised their price target to $110 a share. The stock currently trades near $86 and has fallen 17.4% since the start of the year. The broader S&P 500 has lost 2.5% year-to-date.
More from Video
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.